ID: ALA215195

Max Phase: Preclinical

Molecular Formula: C14H15ClN2O3

Molecular Weight: 294.74

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCOC(=O)C1=C(C)NC(=O)NC1c1ccccc1Cl

Standard InChI:  InChI=1S/C14H15ClN2O3/c1-3-20-13(18)11-8(2)16-14(19)17-12(11)9-6-4-5-7-10(9)15/h4-7,12H,3H2,1-2H3,(H2,16,17,19)

Standard InChI Key:  BAKBIOFRSIUKMG-UHFFFAOYSA-N

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 294.74

Molecular Weight (Monoisotopic): 294.0771

AlogP: 2.53

#Rotatable Bonds: 3

Polar Surface Area: 67.43

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.53

CX Basic pKa:

CX LogP: 1.84

CX LogD: 1.84

Aromatic Rings: 1

Heavy Atoms: 20

QED Weighted: 0.84

Np Likeness Score: -1.26

References

1. Sujatha K, Shanmugam P, Perumal PT, Muralidharan D, Rajendran M..  (2006)  Synthesis and cardiac effects of 3,4-dihydropyrimidin-2(1H)-one-5 carboxylates.,  16  (18): [PMID:16824758] [10.1016/j.bmcl.2006.06.059]

2. PubChem BioAssay data set, 

3. Putatunda S, Chakraborty S, Ghosh S, Nandi P, Chakraborty S, Sen PC, Chakraborty A..  (2012)  Regioselective N1-alkylation of 3,4-dihydropyrimidine-2(1H)-ones: screening of their biological activities against Ca(2+)-ATPase.,  54  [PMID:22658336] [10.1016/j.ejmech.2012.04.043]

4. Kumarasamy D, Roy BG, Rocha-Pereira J, Neyts J, Nanjappan S, Maity S, Mookerjee M, Naesens L..  (2017)  Synthesis and in vitro antiviral evaluation of 4-substituted 3,4-dihydropyrimidinones.,  27  (2): [PMID:27979594] [10.1016/j.bmcl.2016.12.010]

Source

Source(2):

• Scientific Literature
• PubChem BioAssays